Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
作者信息
Poewe W
出版信息
J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):430. doi: 10.1136/jnnp.72.4.430.
Abstract
摘要
相似文献
1
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):430. doi: 10.1136/jnnp.72.4.430.
2
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):459-62. doi: 10.1136/jnnp.72.4.459.
3
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6-12. doi: 10.1136/jnnp.64.1.6.
4
Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
Mov Disord. 2004 Mar;19 Suppl 8:S65-7. doi: 10.1002/mds.20012.
5
Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Clin Ther. 2007 Jul;29(7):1325-37. doi: 10.1016/j.clinthera.2007.07.020.
6
A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Clin Neuropharmacol. 2015 Sep-Oct;38(5):170-6. doi: 10.1097/WNF.0000000000000101.
7
Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Curr Med Res Opin. 2005 Mar;21(3):433-8. doi: 10.1185/030079905X36396.
8
Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
J Clin Pharm Ther. 2007 Aug;32(4):387-402. doi: 10.1111/j.1365-2710.2007.00835.x.
9
Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Mov Disord. 2015 Feb;30(2):206-13. doi: 10.1002/mds.26085. Epub 2014 Dec 5.
10
Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial.
Mov Disord. 2009 May 15;24(7):1098-9; author reply 1100. doi: 10.1002/mds.22339.
引用本文的文献
1
Conversion to AbobotulinumtoxinA Increases Waning Time and Efficacy for Cervical Dystonia.
Mov Disord Clin Pract. 2023 Mar 1;10(5):756-763. doi: 10.1002/mdc3.13696. eCollection 2023 May.
2
A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.
J Rehabil Med. 2021 Jan 1;53(1):jrm00134. doi: 10.2340/16501977-2753.
3
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
Toxins (Basel). 2016 Mar 4;8(3):65. doi: 10.3390/toxins8030065.
4
Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Mov Disord. 2015 Feb;30(2):206-13. doi: 10.1002/mds.26085. Epub 2014 Dec 5.
5
Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.
J Neurol. 2008 Dec;255(12):1932-9. doi: 10.1007/s00415-008-0031-7. Epub 2008 Oct 7.
Zotero 插件